Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Acalabrutinib in Combination With Tafasitamab in Patients With Previously Treated Marginal Zone Lymphomas (MZL)

Next Previous
X
Search
Trial Profile

Phase II Trial of Acalabrutinib in Combination With Tafasitamab in Patients With Previously Treated Marginal Zone Lymphomas (MZL)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Tafasitamab (Primary)
  • Indications Marginal zone B-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Oct 2023 Status changed from recruiting to active, no longer recruiting.
    • 08 Oct 2021 Status changed from not yet recruiting to recruiting.
    • 27 Aug 2021 Planned initiation date changed from 15 Jul 2021 to 15 Sep 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top